Castle Biosciences is a skin cancer diagnostics company focused on providing physicians and patients with personalized, clinically actionable genomic information enabling more accurate treatment plan decisions. From its formation in 2008, Castle Biosciences has applied emerging artificial intelligence techniques in molecular diagnostics to improve patient care and outcomes. Our DecisionDx family of molecular diagnostic tests have the ability to meaningfully impact how cancers are diagnosed and managed (castletestinfo.com).

DecisionDx®-Melanoma predicts risk of recurrence or metastasis that can inform decisions regarding sentinel lymph node biopsy and the intensity of follow-up, surveillance imaging, referral, and adjuvant therapy for patients with invasive cutaneous melanoma. The test uses tumor biology to provide an individual risk of melanoma recurrence beyond traditional factors such as AJCC staging criteria and integrates the 31-GEP score with clinicopathologic factors (i31-GEP) to determine the likelihood of sentinel lymph node positivity.  DecisionDx-Melanoma is supported by consistent evidence in 30 publications including two meta-analyses showing Level 1 evidence classification.

We provide the most comprehensive gene expression profile (GEP) diagnostic workflow to aid in characterizing difficult-to-diagnose melanocytic lesions . Our diagnostic offering includes two tests, myPath® Melanoma and DecisionDx® DiffDx™-Melanoma, leveraging the strengths of both to provide a highly accurate, objective evaluation for a more confident and actionable patient management plan.

DecisionDx®-SCC predicts metastatic risk for patients with cutaneous squamous cell carcinoma who have one or more risk factors. The test complements factors commonly used for risk assessment in SCC. The incorporation of DecisionDx-SCC results with traditional risk factors provides additional risk prediction to better inform choices about treatment and follow-up care.

DecisionDx-UM predicts risk of metastasis for patients with uveal melanoma, a rare eye cancer. The test is standard of care in a majority of ocular oncology practices.

Castle Biosciences has active research and development programs for tests in other dermatologic diseases with high clinical need, including in patients with moderate to severe psoriasis, atopic dermatitis and related conditions. The company is based in Friendswood, Texas with laboratory operations in Phoenix, Arizona (www.CastleBiosciences.com).